scholarly journals Cytology of peritoneal implants of borderline serous tumor of ovaries in ascitic fluid

CytoJournal ◽  
2021 ◽  
Vol 18 ◽  
pp. 17
Author(s):  
Sudha Sharma ◽  
Dibyanshu Sekhar Mohapatra ◽  
Nalini Gupta ◽  
Radhika Srinivasan ◽  
Arvind Rajwanshi ◽  
...  
Keyword(s):  
Ascitic Fluid ◽  
Serous Carcinoma ◽  
Serous Adenocarcinoma ◽  
Nuclear Pleomorphism ◽  
Peritoneal Implants ◽  
Serous Tumor ◽  
Liquid Based Cytology ◽  
Serous Tumors ◽  
Nuclear Features ◽  
Fluid Cytology

Objectives: Peritoneal fluid cytology is done routinely in cases with serous carcinoma of ovary. However, morphologic features of borderline serous tumors (BSTs) of ovary in ascitic fluid have been rarely described. The aim of our study was to evaluate the morphologic features of BST with and without ascitic fluid involvement (BST+ and BST-, respectively) and compare with those of serous carcinomas, both in conventional and liquid-based cytology (LBC) smears. Material and Methods: Out of 30 BST cases reported in 3 years, seven cases had BST+. We compared the cytomorphology of seven cases of BST+, seven cases of BST-, and seven cases of serous adenocarcinoma with positive ascitic fluid cytology. Both conventional and LBC smears were studied in all cases and compared. Histopathology of omentum in these cases was also studied. Results: Most cases with BST+ had regular papillary fragment borders with nuclei showing mild-to-moderate pleomorphism, fine nuclear chromatin with small nucleoli as compared with serous carcinomas all of which had irregular borders with moderate-to-severe nuclear pleomorphism, coarse chromatin, and macronucleoli. Conclusion: A combination of cytoarchitectural and nuclear features can help in suspecting BST in ascitic fluid. Ascitic fluid cytology together with tissue histology can increase the rate of the detection of peritoneal implants.

Assessing the landscape of ovarian serous borderline tumors

2019 ◽  
Vol 29 (3) ◽  
pp. 572-578 ◽  
Author(s):  
Irini Messini ◽  
Triada Doulgeraki ◽  
Dimitris Chrysanthakis ◽  
Petros Yiannou ◽  
Theofani Gavresea ◽  
...  
Keyword(s):  
Univariate Analysis ◽  
Lymph Node Involvement ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumors ◽  
Non Invasive ◽  
Node Involvement ◽  
Serous Tumor ◽  
Serous Tumors ◽  
Micropapillary Pattern

AimTo compare distinct clinicopathological features between atypical proliferative serous tumors and non-invasive low-grade ovarian serous carcinomas.MethodsOur study group comprised 203 cases of serous borderline tumors sub-classified as atypical proliferative serous tumors or as non-invasive low-grade serous carcinomas. All pathological features related to borderline tumors were re-evaluated by two gynecological pathologists. Data concerning recurrences and survival were retrieved from the medical records of the patients.ResultsWhen comparing atypical proliferative serous tumors to non-invasive low-grade serous carcinomas, the latter were statistically related to advanced stage at diagnosis, bilateral disease, exophytic pattern of growth, microinvasive carcinoma, and the presence of invasive implants. In univariate analysis, recurrences were statistically related to the exophytic pattern of growth, to microinvasion, and to the presence of implants (both invasive and non-invasive). Nevertheless, in multivariate analysis, only microinvasion and the presence of invasive implants were related to recurrence. Women who eventually succumbed to the disease were only those with invasive implants. Their ovarian tumor was either a non-invasive low-grade serous carcinoma or an atypical proliferative serous tumor with ‘minimal’ micropapillary pattern. Neither lymph node involvement nor endosalpingiosis seemed to influence the course of the disease.ConclusionsThe results of our study underline the increased possibility of non-invasive low-grade serous carcinomas to be related with features indicative of aggressive behavior as opposed to atypical proliferative serous tumors. Nevertheless, irrespective of tumor histology, the presence of invasive implants and microinvasion were the only independent prognostications of recurrence.

scholarly journals Ascitic Fluid Cytology Seen in a Tertiary Hospital in Nigeria

2020 ◽  
pp. 345-350
Author(s):  
CC Nwafor ◽  
K Obioha ◽  
TO Akhiwu
Keyword(s):  
Sex Ratio ◽  
Patient Care ◽  
Ascitic Fluid ◽  
Age Groups ◽  
Tertiary Hospital ◽  
Age Group ◽  
Malignant Cells ◽  
Female Ratio ◽  
Male To Female ◽  
Fluid Cytology

Ascites is a symptom that can originate due to diverse pathologies. A lot of investigations including ascitic fluid cytology (AFC) can be done on it to help determine its origin. The aim of this study, is to document the findings and highlight the importance of AFC in patient care in Uyo. All AFC reports and slides in the Department of Histopathology, University of Uyo were retrieved, reviewed and used for this study. The age ranged from 1.5 – 80 years with mean age, 41.79 (±17.23) years. About 71.8% of the ascitic fluid (AF) specimens were from patients between the 3rd and 6th decade. Females predominated in all age groups expect 10-19 year's group, with a male to female sex ratio of 1:2.4. Malignant cells were seen in 28.7% of all the samples, while 51.2% were negative for malignant cells. Malignant cells were seen in 4 (6.7%), 11 (18.3%) and 6 (10%) of the AFC performed due to various liver pathologies, ovarian malignancies and intra-abdominal malignancies respectively. Malignant cells were found more in females with a male to female ratio of 1: 3.6. Age group 40-49 years accounted for most of the malignant cases (26.6%). The pattern of AFC in Uyo is similar to the pattern in other parts of Nigeria

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

2008 ◽  
Vol 18 (3) ◽  
pp. 487-491 ◽  
Author(s):  
R. SALANI ◽  
R. J. KURMAN ◽  
R. GIUNTOLI ◽  
G. GARDNER ◽  
R. BRISTOW ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Mutation Frequency ◽  
Clinical Stage ◽  
Serous Carcinoma ◽  
Low Grade ◽  
High Grade ◽  
Mutation Status ◽  
Tumor Dna ◽  
Serous Tumors

The TP53 mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%, but a stringent analysis of TP53 using purified epithelial samples has not yet been performed to accurately assess the mutation frequency and to correlate it with the histologic grade. The purpose of this study was to assess the TP53 mutational profile in a relatively large series of high-grade (53 primary and 18 recurrent) and 13 low-grade ovarian serous tumors using DNA isolated from affinity-purified tumor cells and to correlate it with in vitro drug resistance. All samples were affinity purified, and the tumor DNA was analyzed for TP53 mutations in exons 4–9. In vitro drug resistance assays to carboplatin, cisplatin, paclitaxel, and taxotere were performed on the same tumor samples and correlated with the TP53 mutation status. TP53 mutations were detected in 57 (80.3%) of 71 high-grade carcinomas and in one (7.8%) of 13 low-grade serous tumors (an invasive low-grade serous carcinoma). The mutations were predominantly missense mutations (59.6%). TP53 mutations were associated with high-grade serous carcinomas and recurrent disease (P < 0.0001). There was no statistically significant correlation between TP53 mutation status and drug resistance assays or clinical stage (P > 0.25). The frequency of TP53 mutations using purified tumor DNA from ovarian serous carcinomas was 80.3%, which is much higher than previously reported. Furthermore, we found that TP53 is not directly involved in the development of drug resistance in high-grade ovarian serous carcinomas.

scholarly journals Bilateral low grade serous adenocarcinoma of the ovaries in a badger (Meles meles L.) and its association with a borderline serous ovarian tumour: a case report

2014 ◽  
Vol 59 (No. 1) ◽  
pp. 44-50 ◽  
Author(s):  
K. Kutlvasr ◽  
K. Bukovjan ◽  
R. Kodet
Keyword(s):  
Case Report ◽  
Primary Tumour ◽  
Tumour Cells ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Precursor Lesion ◽  
Wild Female ◽  
Serous Adenocarcinoma ◽  
Human Pathology ◽  
Proliferation Activity

Here, we describe a case of a wild female badger (a sow) with disseminated serous adenocarcinoma of the ovary which corresponds to a group of low grade serous carcinomas of the ovary in humans. Beside grossly apparent dissemination of the disease we observed a scale of histological features classifiable as a precursor lesion &ndash; borderline serous tumour of the ovary with implant metastases at the peritoneum, and features of the borderline tumour transformation in the carcinoma. The latter features included invasion of some of the metastatic peritoneal implants into the adipose tissue of the mesentery, retroperitoneum, and in the muscle of diaphragm with lymphangioinvasion and with blood-borne metastatic disease in the lungs. The primary tumour and its metastases had a uniform cytological appearance without atypia of the tumour cells. Mitotic activity was exceptional. The proliferation activity as demonstrated by immunohistochemical investigation of Ki-67 protein expression (revealing all active phases of the cell cycle &ndash; G1, S, G2, M) showed a low proliferation activity of the tumour cells, comparable with findings in low grade carcinomas or borderline tumours of the ovaries in women. WT1 protein was expressed in the whole tumour cell population. All these features were diagnostic of serous carcinoma of the ovary with low grade malignant potential. Tumours of the ovaries in wildlife have been described previously but they are infrequent and are rarely classified histopathologically. This case report offers a parallel with serous carcinomas in human pathology including features of transformation from a precursor lesion of a borderline serous tumour into a serous low grade carcinoma. &nbsp;

scholarly journals Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification

2016 ◽  
Vol 124 (10) ◽  
pp. 699-710 ◽  
Author(s):  
Tommaso Bizzarro ◽  
Maurizio Martini ◽  
Sara Capodimonti ◽  
Patrizia Straccia ◽  
Celestino Pio Lombardi ◽  
...  
Keyword(s):  
Thyroid Neoplasm ◽  
Young Investigator ◽  
Liquid Based Cytology ◽  
Morphologic Analysis ◽  
Nuclear Features

miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma

2017 ◽  
Vol 70 ◽  
pp. 98-104 ◽  
Author(s):  
Florence A. Arts ◽  
Lisa Keogh ◽  
Paul Smyth ◽  
Sharon O'Toole ◽  
Robert Ta ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Complex Protein ◽  
Serous Tumor

Cancer Stem Cell–Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases

2017 ◽  
Vol 27 (9) ◽  
pp. 2006-2013 ◽  
Author(s):  
Nataša Kenda Šuster ◽  
Snježana Frković Grazio ◽  
Irma Virant-Klun ◽  
Ivan Verdenik ◽  
Špela Smrkolj
Keyword(s):  
Stem Cell ◽  
Cancer Stem Cell ◽  
Signal Intensity ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Clinical Parameters ◽  
High Grade ◽  
Ovarian Serous Carcinoma ◽  
Nanog Expression ◽  
Serous Tumors

ObjectiveThe objectives of this study were to assess cancer stem cell–related marker NANOG expression in ovarian serous tumors and to evaluate its prognostic significance in relation to ovarian serous carcinoma.MethodsNANOG protein expression was immunohistochemically evaluated in the ovarian tissue microarrays of 20 patients with benign ovarian serous tumors, 30 patients with borderline ovarian serous tumors, and 109 patients with ovarian serous carcinomas, from which 106 were of high-grade and 3 of low-grade morphology Immunohistochemical reaction was scored according to signal intensity and the percentage of positive cells in tumor samples. Pursuant to our summation of signal intensity and positive cell occurrence, we divided our samples into 4 groups: NANOG-negative, NANOG–slightly positive, NANOG–moderately positive, and NANOG–strongly positive group. Complete clinical data were obtained for the ovarian serous carcinoma group, and correlation between clinical data and NANOG expression was analyzed.ResultsA specific brown nuclear, or cytoplasmic reaction, was considered a positive NANOG staining. In terms of the ovarian serous carcinoma group, 69.7% were NANOG positive, 22.9% slightly positive, 22.9% moderately positive, and 23.9% strongly positive. All NANOG-positive cases were of high-grade morphology. Benign and borderline tumors and low-grade serous carcinomas were NANOG negative. There was no significant correlation between NANOG expression and clinical parameters in terms of the ovarian serous carcinoma group.ConclusionsPositive NANOG expression is significantly associated with high-grade ovarian serous carcinoma and is absent in benign, borderline, and low-grade serous lesions. In our study, there was no correlation between NANOG expression and clinical parameters, including its use in the prognosis of ovarian serous carcinoma.

Sign in / Sign up

Export Citation Format

Share Document